Enterprise Value
391.6B
Cash
26.22B
Avg Qtr Burn
N/A
Short % of Float
0.75%
Insider Ownership
0.08%
Institutional Own.
71.70%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OPSUMIT (macitentan) Details Pulmonary arterial hypertension | Approved Quarterly sales | |
CARVYKTI (ciltacabtagene autoleucel) Details Cancer, Multiple myeloma | Approved Quarterly sales | |
TALVEY (talquetamab) Details Multiple myeloma, Cancer | Approved Quarterly sales | |
DARZALEX (daratumumab) Details Cancer, Multiple myeloma | Approved Quarterly sales | |
BALVERSA (erdafitinib) Details Cancer, Urothelial cancer | Approved Quarterly sales | |
UPTRAVI (selexipag) Details Pulmonary arterial hypertension | Approved Quarterly sales | |
AKEEGA (niraparib/abiraterone) Details Cancer, Castration-resistant prostate cancer | Approved Quarterly sales | |
TECVAYLI® (teclistamab-cqyv) Details Multiple myeloma, Cancer | Approved Quarterly sales | |
SPRAVATO (esketamine) Details Treatment Resistant Depression | Approved Quarterly sales | |
TREMFYA (guselkumab) Details Psoriasis | Approved Quarterly sales | |
IMBRUVICA (ibrutinib) Details Chronic lymphocytic leukemia | Approved Quarterly sales | |
TREMFYA (guselkumab) Details Ulcerative colitis | BLA Acceptance for review | |
RYBREVANT (amivantamab) Details Non-small cell lung carcinoma, Cancer | BLA Acceptance for review | |
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Details Multiple myeloma | BLA Acceptance for review | |
OPSUMIT (macitentan) w/tadalafil FDC Details Pulmonary arterial hypertension | NDA Submission | |
TREMFYA (guselkumab) Details Crohns disease | Phase 3 Data readout | |
VARIPULSE™ Details Atrial fibrillation | Phase 3 Update | |
RYBREVANT (amivantamab) + Chemotherapy Details Cancer, Non-small cell lung carcinoma | Phase 3 Update | |
Nipocalimab Details Myasthenia gravis, Autoimmune disease | Phase 3 Update | |
TAR-200 (RIS/gemcitabine plus cetrelimab) Details Cancer, Non-muscle invasive bladder cancer | Phase 2b Data readout | |
nipocalimab Details Warm autoimmune hemolytic anemia | Phase 2 Update | |
BALVERSA (erdafitinib) Details Solid tumor/s | Phase 2 Update | |
Nipocalimab Details Autoimmune disease, Sjögren-Larsson Syndrome | Phase 2 Update | |
RYBREVANT ( SC amivantamab) + lazertinib) Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
NM26 Details Atopic dermatitis, Skin disease/disorder | Phase 2 Initiation | |
nipocalimab Details Rheumatoid arthritis | Phase 2a Data readout | |
TAR-210 (RIS/erdafitinib) Details Cancer, Non-muscle invasive bladder cancer | Phase 1 Data readout | |
IMBRUVICA (ibrutinib) Details Lymphoma, Mantle cell lymphoma, Marginal zone lymphoma | Failed Discontinued |